Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Evommune (EVMN) Gains from Investment Securities (2024 - 2025)

Evommune (EVMN) has disclosed Gains from Investment Securities for 2 consecutive years, with $136000.0 as the latest value for Q4 2025.

Quarterly Gains from Investment Securities rose 25.93% to $136000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14723.0 through Sep 2025, changed N/A year-over-year, with the annual reading at $6.6 million for FY2025, 77.61% up from the prior year.
Gains from Investment Securities for Q4 2025 was $136000.0 at Evommune, up from $14723.0 in the prior quarter.
The five-year high for Gains from Investment Securities was $136000.0 in Q4 2025, with the low at $14723.0 in Q3 2025.